Posted by Michael Wonder on 15 Oct 2020
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
15 October 2020 - NICE has today issued draft guidance which now recommends siponimod (Mayzent; Novartis) for treating secondary progressive multiple sclerosis.
Siponimod, which is taken orally, is licensed to treat secondary progressive multiple sclerosis in adults with evidence of active disease (where people have relapses or features of inflammatory activity that show up on imaging). Around 11,000 people with secondary progressive multiple sclerosis will now be eligible for treatment with Siponimod.
Clinical trial results show that siponimod reduces the number of relapses and slows worsening disability compared with placebo.
